A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system

Article metrics

Abstract

Sustained silencing of gene expression throughout the brain using small interfering RNAs (siRNAs) has not been achieved. Here we describe an siRNA architecture, divalent siRNA (di-siRNA), that supports potent, sustained gene silencing in the central nervous system (CNS) of mice and nonhuman primates following a single injection into the cerebrospinal fluid. Di-siRNAs are composed of two fully chemically modified, phosphorothioate-containing siRNAs connected by a linker. In mice, di-siRNAs induced the potent silencing of huntingtin, the causative gene in Huntington’s disease, reducing messenger RNA and protein throughout the brain. Silencing persisted for at least 6 months, with the degree of gene silencing correlating to levels of guide strand tissue accumulation. In cynomolgus macaques, a bolus injection of di-siRNA showed substantial distribution and robust silencing throughout the brain and spinal cord without detectable toxicity and with minimal off-target effects. This siRNA design may enable RNA interference-based gene silencing in the CNS for the treatment of neurological disorders.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: A divalent siRNA chemical configuration enables gene silencing in the mouse brain.
Fig. 2: Di-siRNA efficacy is sustained in mice 6 months after a single bilateral ICV injection.
Fig. 3: Gene silencing in the NHP CNS with di-siRNAs.
Fig. 4: Di-siRNA enables silencing in the spinal cord of NHPs.
Fig. 5: Assessment of brain toxicity 1 month after a single ICV injection of di-siRNA in NHPs.
Fig. 6: RNA-seq shows limited off-target effects of di-siRNA.

Data availability

The RNA-seq data from nonhuman primate samples have been deposited in GEO under accession code GSE130132, including processed transcriptome read counts.

References

  1. 1.

    Khvorova, A. & Watts, J. K. The chemical evolution of oligonucleotide therapies of clinical utility. Nat. Biotechnol. 35, 238–248 (2017).

  2. 2.

    Ostergaard, M. E. et al. Efficient synthesis and biological evaluation of 5’-galnac conjugated antisense oligonucleotides. Bioconjug. Chem. 26, 1451–1455 (2015).

  3. 3.

    Rajeev, K. G. et al. Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo. Chembiochem. 16, 903–908 (2015).

  4. 4.

    Kordasiewicz, H. B. et al. Sustained therapeutic reversal of Huntington’s disease by transient repression of huntingtin synthesis. Neuron. 74, 1031–1044 (2012).

  5. 5.

    Finkel, R. S. et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N. Engl. J. Med. 377, 1723–1732 (2017).

  6. 6.

    Coelho, T. et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N. Engl. J. Med. 369, 819–829 (2013).

  7. 7.

    Alterman, J. F. et al. Hydrophobically modified siRNAs silence huntingtin mRNA in primary neurons and mouse brain. Mol. Ther. Nucleic Acids 4, e266 (2015).

  8. 8.

    Nikan, M. et al. Docosahexaenoic acid conjugation enhances distribution and safety of siRNA upon local administration in mouse brain. Mol. Ther. Nucleic Acids 5, e344 (2016).

  9. 9.

    Osborn, M. F. & Khvorova, A. Improving small interfering RNA delivery in vivo through lipid conjugation. Nucleic Acid Ther. 28, 128–136 (2018).

  10. 10.

    Nikan, M. et al. Synthesis and evaluation of parenchymal retention and efficacy of a metabolically stable O-Phosphocholine-N-docosahexaenoyl-l-serine siRNA conjugate in mouse brain. Bioconjug. Chem. 28, 1758–1766 (2017).

  11. 11.

    Ly, S. et al. Visualization of self-delivering hydrophobically modified siRNA cellular internalization. Nucleic Acids Res. 45, 15–25 (2017).

  12. 12.

    Eckstein, F. Phosphorothioates, essential components of therapeutic oligonucleotides. Nucleic Acid Ther. 24, 374–387 (2014).

  13. 13.

    Flierl, U. et al. Phosphorothioate backbone modifications of nucleotide-based drugs are potent platelet activators. J. Exp. Med. 212, 129–137 (2015).

  14. 14.

    Sewing, S. et al. Assessing single-stranded oligonucleotide drug-induced effects in vitro reveals key risk factors for thrombocytopenia. PLoS ONE 12, e0187574 (2017).

  15. 15.

    Crooke, S. T., Wang, S., Vickers, T. A., Shen, W. & Liang, X. H. Cellular uptake and trafficking of antisense oligonucleotides. Nat. Biotechnol. 35, 230–237 (2017).

  16. 16.

    Hassler, M. R. et al. Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo. Nucleic Acids Res. 46, 2185–2196 (2018).

  17. 17.

    Behlke, M. A. Progress towards in vivo use of siRNAs. Mol. Ther. 13, 644–670 (2006).

  18. 18.

    Winkler, J., Stessl, M., Amartey, J. & Noe, C. R. Off-target effects related to the phosphorothioate modification of nucleic acids. Chem. Med. Chem. 5, 1344–1352 (2010).

  19. 19.

    Amarzguioui, M., Holen, T., Babaie, E. & Prydz, H. Tolerance for mutations and chemical modifications in a siRNA. Nucl. Acids Res. 31, 589–595 (2003).

  20. 20.

    Harborth, J. et al. Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucl. Acid Drug Devel. 13, 83–105 (2003).

  21. 21.

    Nair, J. K. et al. Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc-siRNA conjugates. Nucleic Acids Res. 45, 10969–10977 (2017).

  22. 22.

    Fitzgerald, K. et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N. Engl. J. Med. 376, 41–51 (2017).

  23. 23.

    Ray, K. K. et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N. Engl. J. Med. 376, 1430–1440 (2017).

  24. 24.

    Lee, Y. C. et al. Binding of synthetic oligosaccharides to the hepatic Gal/GalNAc lectin. Dependence on fine structural features. J. Biol. Chem. 258, 199–202 (1983).

  25. 25.

    Roehl, I., Schuster, M. & Seiffert, S. US Patent 20110201006 A1 (2011).

  26. 26.

    Liu, C. C., Liu, C. C., Kanekiyo, T., Xu, H. & Bu, G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 9, 106–118 (2013).

  27. 27.

    Mahley, R. W., Weisgraber, K. H. & Huang, Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer’s disease. Proc. Natl Acad. Sci. USA 103, 5644–5651 (2006).

  28. 28.

    Zetterberg, H., Jacobsson, J., Rosengren, L., Blennow, K. & Andersen, P. M. Association of APOE with age at onset of sporadic amyotrophic lateral sclerosis. J. Neurol. Sci. 273, 67–69 (2008).

  29. 29.

    Didiot, M. C. et al. Nuclear localization of huntingtin mRNA Is specific to cells of neuronal origin. Cell. Rep. 24, 2553–2560 e2555 (2018).

  30. 30.

    Achuta, V. S. et al. Tissue plasminogen activator contributes to alterations of neuronal migration and activity-dependent responses in fragile X mice. J. Neurosci. 34, 1916–1923 (2014).

  31. 31.

    Gu, X. et al. N17 Modifies mutant huntingtin nuclear pathogenesis and severity of disease in HD BAC transgenic mice. Neuron 85, 726–741 (2015).

  32. 32.

    DiFiglia, M. et al. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 14, 1075–1081 (1995).

  33. 33.

    Herndon, E. S. et al. Neuroanatomic profile of polyglutamine immunoreactivity in Huntington disease brains. J. Neuropathol. Exp. Neurol. 68, 250–261 (2009).

  34. 34.

    Weyer, A. & Schilling, K. Developmental and cell type-specific expression of the neuronal marker NeuN in the murine cerebellum. J. Neurosci. Res. 73, 400–409 (2003).

  35. 35.

    Takala, R. S. et al. Glial fibrillary acidic protein and ubiquitin C-Terminal hydrolase-L1 as outcome predictors in traumatic brain injury. World Neurosurg. 87, 8–20 (2016).

  36. 36.

    Lind, D., Franken, S., Kappler, J., Jankowski, J. & Schilling, K. Characterization of the neuronal marker NeuN as a multiply phosphorylated antigen with discrete subcellular localization. J. Neurosci. Res. 79, 295–302 (2005).

  37. 37.

    Dou, C. L., Li, S. & Lai, E. Dual role of brain factor-1 in regulating growth and patterning of the cerebral hemispheres. Cereb. Cortex 9, 543–550 (1999).

  38. 38.

    Janas, M. M. et al. Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity. Nat. Commun. 9, 723 (2018).

  39. 39.

    Birmingham, A. et al. 3’ UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat. Methods 3, 199–204 (2006).

  40. 40.

    Zuccato, C., Valenza, M. & Cattaneo, E. Molecular mechanisms and potential therapeutical targets in Huntington’s disease. Physiol. Rev. 90, 905–981 (2010).

  41. 41.

    Evers, M. M. et al. AAV5-miHTT gene therapy demonstrates broad distribution and strong human mutant huntingtin lowering in a huntington’s disease minipig model. Mol. Ther. 26, 2163–2177 (2018).

  42. 42.

    Southwell, A. L. et al. Huntingtin suppression restores cognitive function in a mouse model of Huntington’s disease. Sci. Transl. Med. 10, eaar3959 (2018).

  43. 43.

    Pfister, E. L. et al. Artificial miRNAs reduce human mutant huntingtin throughout the striatum in a transgenic sheep model of Huntington’s disease. Hum. Gene. Ther. 29, 663–673 (2018).

  44. 44.

    Grondin, R. et al. Six-month partial suppression of huntingtin is well tolerated in the adult rhesus striatum. Brain 135, 1197–1209 (2012).

  45. 45.

    Tabrizi, S. et al. Effects of IONIS-HTTRx in patients with early Huntington’s disease, results of the first HTT-lowering drug trial (CT.002). Neurology 90, CT.002 (2018).

  46. 46.

    Bhagat, L. et al. Novel oligonucleotides containing two 3’-ends complementary to target mRNA show optimal gene-silencing activity. J. Med. Chem. 54, 3027–3036 (2011).

  47. 47.

    Malcolm, D. W., Sorrells, J. E., Van Twisk, D., Thakar, J. & Benoit, D. S. Evaluating side effects of nanoparticle-mediated siRNA delivery to mesenchymal stem cells using next generation sequencing and enrichment analysis. Bioeng. Transl. Med. 1, 193–206 (2016).

  48. 48.

    Wang, G., Liu, X., Gaertig, M. A., Li, S. & Li, X. J. Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis. Proc. Natl Acad. Sci. USA 113, 3359–3364 (2016).

  49. 49.

    Pfister, E. L. et al. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington’s disease patients. Curr. Biol. 19, 774–778 (2009).

  50. 50.

    Godinho, B. et al. Transvascular delivery of hydrophobically modified siRNAs: Gene silencing in the rat brain upon disruption of the blood-brain barrier. Mol. Ther. 26, 2580–2591 (2018).

Download references

Acknowledgements

This project was funded by the NIH/NINDS (grant no. R01 NS104022; for A.K.), NIH/OD (grant no. S10 OD020012; for A.K.), CHDI (Research Agreement no. A-6119; for N.A.), Alzheimer’s Drug Discovery Foundation (grant no. 20170101; for A.K.), Milton-Safenowitz Fellowship (no. 17-PDF-363; for B.M.D.C.G.) and The Berman–Topper Fund (for A.K. and N.A.). We would like to thank the University of Massachusetts Medical School Animal Medicine Department and veterinary technicians for their contributions to the large-animal studies. We would like to thank M.-C. Didiot for her mouse brain cartoon, E. Mohn and S. Hildebrand for editing the manuscript and Charles River Laboratories for help with neuropathology.

Author information

J.F.A., B.M.D.C.G., M.R.H. and A.K. conceived the project. J.F.A., B.M.D.C.G., M.R.H., C.M.F., M.D, N.A. and A.K. contributed to the experimental design. J.F.A., B.M.D.C.G., C.M.F, E.S., C.M.F., R.A.H., A.H.C., F.C., R.M., L.R., P.Y., A.A.T., E.G.K. and A.A.P. contributed experimentally. M.R.H. and D.E. synthesized the compounds. J.F.A., B.M.D.C.G., C.M.F., A.H.C., R.M.K., H.L.G.E., R.P.M., N.C.B., S.M.J., M.J.G. and M.S.E. carried out large-animal studies. G.G. and C.M. provided naive nonhuman primate samples. J.F.A., B.M.D.C.G., M.R.H., C.M.F. and A.K. wrote the manuscript.

Correspondence to Anastasia Khvorova.

Ethics declarations

Competing interests

A.K., J.F.A., M.R.H. and B.M.D.C.G. have filed a patent application for branched oligonucleotides.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary Information

Supplementary Figures 1–21, Supplementary Tables 1 and 2 and Supplementary Notes 1 and 2

Reporting Summary

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Alterman, J.F., Godinho, B.M.D.C., Hassler, M.R. et al. A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system. Nat Biotechnol 37, 884–894 (2019) doi:10.1038/s41587-019-0205-0

Download citation